The expression of prostatic markers (PSA 5–60%, PSMA 20–80%, AR 90–100%, and NKX3.1 70–100%) identified PGCC as of prostatic origin and allowed to differentiate it from pleomorphic giant cell carcinomas from other organs. The gene discussed is NKX3-1; the disease is lung giant cell carcinoma.